Market Research Logo

US Procedure Numbers for Orthopedic Biomaterials 2017 - MedPro

US Procedure Numbers for Orthopedic Biomaterials 2017 - MedPro

The full report suite on the U.S. market for orthopedic biomaterials includes bone graft substitutes, which is represented by allografts, demineralized bone matrix, and synthetic bone graft market. The report also includes orthopedic growth factors, cellular allografts, orthopedic cell therapy, hyaluronic acid viscosupplementation, orthopedic cartilage repair, and spinal machined bone allograft markets.

General Report Contents

  • Market Analyses include: Unit Sales, ASPs, Market Value & Growth Trends
  • Market Drivers & Limiters for each chapter segment
  • Competitive Analysis for each chapter segment
  • Section on recent mergers & acquisitions
Orthopedic biomaterials are associated with high research and development (R&D) costs, which have subsequently led to premium pricing to recoup these initial costs. This is the case for competitors in the cellular allograft, cell therapy and growth factor segments of the U.S. orthopedic biomaterials market. In particular, orthopedic growth factors have had relatively high average selling prices (ASP) since their introduction to the market due to the high costs of recombinant growth factor technologies. The high R&D costs associated with the growth factor segment provide entry barriers against potential competitors. Currently there are only two growth factor BMP-2 products in the United States. Since they’re both used in different indications, there is a lack of direct competition, allowing companies such as Medtronic to charge a premium for the Spine indication and recover the large initial costs associated with R&D. The commoditized nature in some parts of the market, such as the allograft and DBM segments, which is due to the lack of product differentiation, has limited growth. The market is being driven by more competitors venturing outside their traditional space to tap into the high growth segments where they can charge a premium. These segments may include the cell therapy and cellular allograft segments, both of which have relatively high ASP.


EXECUTIVE SUMMARY
U.S. ORTHOPEDIC BIOMATERIALS MARKET OVERVIEW
COMPETITIVE ANALYSIS
MARKET TRENDS
MARKET DEVELOPMENTS
PROCEDURE NUMBERS
MARKETS INCLUDED
KEY REPORT UPDATES
VERSION HISTORY
RESEARCH METHODOLOGY
1.1 RESEARCH SCOPE
1.2 IDATA’S 9-STEP METHODOLOGY
Step 1: Project Initiation & Team Selection
Step 2: Prepare Data Systems and Perform Secondary Research
Step 3: Preparation for Interviews & Questionnaire Design
Step 4: Performing Primary Research
Step 5: Research Analysis: Establishing Baseline Estimates
Step 6: Market Forecast and Analysis
Step 7: Identify Strategic Opportunities
Step 8: Final Review and Market Release
Step 9: Customer Feedback and Market Monitoring
DISEASE OVERVIEW
2.1 BASIC ANATOMY
2.1.1 Osteology and Musculoskeletal System
2.2 DISEASE PATHOLOGY AND DISORDERS
2.2.1 General Diagnostic
2.2.2 Osteoporosis
2.2.3 Osteoarthritis
2.2.4 Indication for Bone Graft Procedure
2.2.5 Indication for Cartilage Repair
2.2.6 Degenerative Disc Disease
2.3 PATIENT DEMOGRAPHICS
2.3.1 General Statistics
PROCEDURE NUMBERS
3.1 PROCEDURE DEFINITIONS
3.2 BONE GRAFT PROCEDURE NUMBERS BY TYPE
3.3 BONE GRAFT SUBSTITUTE PROCEDURE NUMBERS
3.3.1 By Material
3.3.2 By Indication
3.4 GROWTH FACTOR BONE GRAFT PROCEDURE NUMBERS
3.5 CELLULAR ALLOGRAFT PROCEDURE NUMBERS
3.6 CELL THERAPY TREATMENT NUMBERS
3.6.1 Platelet-Rich Treatment Numbers by Indication
3.6.2 Bone Marrow Concentrate Treatment Numbers by Indication
3.7 HYALURONIC ACID TREATMENT NUMBERS BY TYPE
3.8 CARTILAGE REPAIR PROCEDURE NUMBERS BY TYPE
3.9 SPINAL MACHINED BONE ALLOGRAFT PROCEDURE NUMBERS BY APPROACH
ABBREVIATIONS
APPENDIX II: COMPANY PRESS RELEASES
List of Charts
Chart 1 1: Orthopedic Biomaterials Market by Segment, U.S., 2013 – 2023
Chart 1 2: Orthopedic Biomaterials Market Overview, U.S., 2016 & 2023
Chart 3 1: Bone Graft Procedure Numbers by Type, U.S., 2013 – 2023
Chart 3 2: Bone Graft Substitute Procedure Numbers by Material, U.S., 2013 – 2023
Chart 3 3: Bone Graft Substitute Procedure Numbers by Indication, U.S., 2013 – 2023
Chart 3 4: Growth Factor Bone Graft Procedure Numbers, U.S., 2013 – 2023
Chart 3 5: Cellular Allograft Procedure Numbers, U.S., 2013 – 2023
Chart 3 6: Cell Therapy Treatment Numbers by Type, U.S., 2013 – 2023
Chart 3 7: Platelet-Rich Plasma Treatment Numbers by Indication, U.S., 2013 – 2023
Chart 3 8: Bone Marrow Concentrate Treatment Numbers by Indication, U.S., 2013 – 2023
Chart 3 9: Hyaluronic Acid Treatment Numbers by Type, U.S., 2013 – 2023
Chart 3 10: Cartilage Repair Procedure Numbers by Type, U.S., 2013 – 2023
Chart 3 11: Spinal Machined Bone Allograft Procedure Numbers by Approach, U.S., 2013 – 2023
List of Figures
Figure 1 1: Orthopedic Biomaterials Market Share Ranking by Segment, U.S., 2016 (1 of 2)
Figure 1 2: Orthopedic Biomaterials Market Share Ranking by Segment, U.S., 2016 (2 of 2)
Figure 1 3: Companies Researched in this Report, U.S., 2016
Figure 1 4: Factors Impacting the Orthopedic Biomaterials Market by Segment, U.S. (1 of 2)
Figure 1 5: Factors Impacting the Orthopedic Biomaterials Market by Segment, U.S. (2 of 2)
Figure 1 6: Recent Events in the Orthopedic Biomaterials Market, U.S., 2013 – 2016
Figure 1 7: Orthopedic Biomaterials Markets Covered, U.S., 2016 (1 of 2)
Figure 1 8: Orthopedic Biomaterials Markets Covered, U.S., 2016 (2 of 2)
Figure 1 9: Orthopedic Biomaterials Markets Covered, U.S., 2016(1 of 3)
Figure 3 1: Bone Graft Procedure Numbers by Type, U.S., 2013 – 2023
Figure 3 2: Bone Graft Substitute Procedure Numbers by Material, U.S., 2013 – 2023
Figure 3 3: Bone Graft Substitute Procedure Numbers by Indication, U.S., 2013 – 2023 (1 of 2)
Figure 3 4: Bone Graft Substitute Procedure Numbers by Indication, U.S., 2013 – 2023 (2 of 2)
Figure 3 5: Growth Factor Bone Graft Procedure Numbers, U.S., 2013 – 2023
Figure 3 6: Cellular Allograft Procedure Numbers, U.S., 2013 – 2023
Figure 3 7: Cell Therapy Treatment Numbers by Type, U.S., 2013 – 2023
Figure 3 8: Platelet-Rich Plasma Treatment Numbers by Indication, U.S., 2013 – 2023
Figure 3 9: Bone Marrow Concentrate Treatment Numbers by Indication, U.S., 2013 – 2023
Figure 3 10: Hyaluronic Acid Treatment Numbers by Type, U.S., 2013 – 2023
Figure 3 11: Cartilage Repair Procedure Numbers by Type, U.S., 2013 – 2023
Figure 3 12: Spinal Machined Bone Allograft Procedure Numbers by Approach, U.S., 2013 – 2023
Figure 5 1: Press Release Summary

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report